INVITED REVIEW
Ahead of print publication  

Risk profiling in patients undergoing penile prosthesis implantation


 Department of Urology, University of California, Irvine Medical Center, Orange, CA 92868, USA

Date of Submission25-Jan-2019
Date of Acceptance21-Jun-2019
Date of Web Publication06-Sep-2019

Correspondence Address:
Faysal A Yafi,
Department of Urology, University of California, Irvine Medical Center, Orange, CA 92868
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/aja.aja_92_19

  Abstract 


Penile prosthesis implantation is the gold standard of surgical therapy for patients with medication-refractory erectile dysfunction. However, this umbrella definition includes significant heterogeneity and associated risk profiles that should be candidly discussed and addressed perioperatively. Factors associated with operative success and patient satisfaction are often surgery specific; however, risk profiling via patient selection, preoperative optimization, proper device selection, and intraoperative consideration are highly correlated. Some examples of common risk profiles include comorbidity(ies) such as cardiovascular disease, diabetes mellitus, prior abdominal surgery, Peyronie's disease, and psychological risk factors. Similarly, integration of surgeon- and patient-amenable characteristics is key to decreasing risk of infection, complication, and need for revision. Finally, patient risk profiling provides a unique context for proper device selection and evidence-based intraoperative considerations.

Keywords: patient selection; penile prosthesis; risk factors


Article in PDF

How to cite this URL:
Huynh LM, Osman MM, Yafi FA. Risk profiling in patients undergoing penile prosthesis implantation. Asian J Androl [Epub ahead of print] [cited 2019 Sep 15]. Available from: http://www.ajandrology.com/preprintarticle.asp?id=266178




  Introduction Top


Penile prosthesis (PP) implantation is the gold standard of surgical therapy for patients refractory to pharmacological therapies, such as phosphodiesterase type 5 (PDE-5) inhibitors.[1],[2],[3] While these procedures are often associated with high levels of patient satisfaction,[4],[5],[6] risks for complications remain.[7],[8] In addition, given the elective nature of PP implantation, there also exists a significant risk for disconnect between preoperative expectations and postoperative reality – a balance which places unique pressures on informed patient consent, preoperative counseling, and risk profiling.[9],[10]

The goal of this review is to explore common risk profiles for patients undergoing PP implantation, in addition to other factors of patient satisfaction and operative success. In doing so, this review will discuss patient selection, pertinent risk factors, preoperative optimization, device selection, and intraoperative considerations.


  Patient Selection and Pertinent Risk Factors Top


Although patient selection for PP implantation is typically straightforward due to patient preference, there are many nuances that require significant attention.[9],[10] Both the American Urological Association (AUA) and the International Society of Sexual Medicine (ISSM) guidelines recommend pursuing PP implantation as an intervention for end-stage erectile dysfunction (ED) and, especially, for patients refractory to conservative therapies.[11],[12] However, this umbrella definition creates significant heterogeneity within the patient population, as it potentially includes patients with ED as a result of other medical comorbidities such as cardiovascular disease, diabetes mellitus, radical prostatectomy, Peyronie's disease, or psychological conditions.[13],[14],[15],[16] Even further, a diagnosis of ED may be indicative of underlying comorbidities that ought to be addressed prior to prosthetic surgery.[14],[15],[16] These added layers of complexity further emphasize the need for evidence-based practices during patient selection and preoperative risk counseling.

History of cardiovascular disease

ED is more common in the elderly population[17],[18] and often occurs with cardiovascular disease.[13] A diagnosis of ED can be indicative of underlying coronary artery disease (even in younger patients) and places this population at an increased risk for future cardiovascular events.[19] While there are no validated tools to estimate risk of cardiovascular complications during PP implantation, several nomograms exist for preoperative cardiovascular assessment and general postoperative management.[20],[21] Knowledge of these risk stratification tools, such as the CHADS2 and CHA2 DS2-VASc (congestive heart failure, hypertension, age [≥75 years], diabetes mellitus, and stroke [vascular disease, age (65–74 years), and sex category]) scores,[22],[23] can be useful referents within the context of patient selection and preoperative counseling during PP implantation. These nomograms and their threshold values are summarized in [Table 1].
Table 1: Cardiovascular risk stratification via CHADS2 and CHA2SDS2-VASc scores

Click here to view


Further, given that penile prosthetic surgery is classified as a high risk for bleeding, special attention needs be paid to patients utilizing antiplatelet and/or anticoagulant (AP/AC) medications.[24] In particular, significant cardiovascular conditions requiring AP/AC use include congestive heart failure, atrial fibrillation, deep vein thrombosis, coronary stents, mechanical heart valves, or pulmonary embolism.[25],[26] In an effort to mitigate the risk of complications of urologic interventions on patients managed with AP/AC, the AUA and International Consultation on Urological Disease (ICUD) recently published recommendations for nonurgent procedures in patients utilizing AP/AC. Their guidelines are summarized in [Table 2].[27] While PP implantation was not previously recommended for men utilizing anticoagulants, the AUA and several other organizations now generally regard this procedure to be safe in this population.[27],[28]
Table 2: Summary of the American Urological Association Guidelines on anticoagulant and antiplatelet use

Click here to view


History of diabetes mellitus

Patients with a history of diabetes mellitus are naturally at high risk for infection, due to immune dysfunction, diabetic neuropathy, and poor circulation.[29],[30],[31] However, it remains unclear whether diabetes and diabetic comorbidity significantly increase rates of infection after PP implantation.[32],[33],[34],[35] After a study from 1992 found that patients with higher glycated hemoglobin (HbA1c) had significantly higher rates of infection, patients with poorly controlled diabetes are often considered at higher risk.[32] A more recent study from 2018 revisited these findings and subsequently established an HbA1c threshold of 8.5% in an effort to characterize patients and further assisted in preoperative optimization.[33] However, evidence continues to remain divided, as several systematic reviews confer no significant increase in infection rates.[36] Despite this lack of consensus, surgeons are still encouraged to optimize patient health prior to nonemergent procedures[37],[38] and large prospective studies assessing impact of diabetic characteristics on postoperative outcomes are highly encouraged.

Previous abdominal surgery

Previous abdominal surgery can be indicative of intraoperative difficulty, especially with regard to reservoir placement.[39] Traditional placement prefers blind introduction of the reservoir into the Retzius space.[39],[40] However, patients with prior abdominal or pelvic surgery are at higher risk for complications during placement; intestinal reservoir-related complications, intraoperative damage to the bladder, iliac vessels, or other surrounding structures are complications of which all implanters must be aware during reservoir placement in the space of Retzius, since they may be further exacerbated by previous surgery, radiation, or trauma.

For patients with a history of significant abdominal surgery, and potentially altered anatomy, such as history of robot-assisted laparoscopic prostatectomy, radical cystectomy, bilateral inguinal hernia repair, and/or colorectal interventions, reservoir placement in a submuscular location is preferred.[40] This space, which is developed above the transversalis fascia and under the rectus fascia, has proven to be both a safe and also effective alternative with high rates of patient satisfaction.[40],[41],[42] During preoperative counseling, these patients should be warned of the side effects of submuscular reservoirs, i.e., the possibility of a palpable reservoir and the rare circumstance requiring reservoir revision secondary to herniation.

Alternatively, for patients with increased risk, Hartman et al.[41] developed an alternative surgical approach to prevent damage to the bladder and iliac vessels. As per this technique, a small, incision is made above the anterior superior iliac spine in both lower lateral quadrants, and a pocket in the potential space of the retroperitoneum was created for placement. The pump is implanted in a subdartos midline scrotal pouch. Although this method required a second fascial incision (and potential attendant increases in operative time and postoperative discomfort), there were no complications or injuries in the 62 patients in the trial. This technique was further explored by Loh-Doyle et al.[43] in patients with urinary diversion, with similar success.

Patients with Peyronie's disease

The development of medication-refractory ED in association with Peyronie's disease is common, with PP implantation being the most popular surgical treatment.[44] According to the AUA guidelines, a malleable PP is often associated with higher dissatisfaction among patients and an inflatable PP is the preferred choice.[45] While overall patient satisfaction is high, dissatisfaction is often linked to shortened penile size, reduced sensitivity, poor concealment, and device deviation,[46] possibilities which should be addressed in detail during the patient selection process. Simple PP insertion is shown to resolve curvature in 33%–90% of patients, but adjunctive surgical techniques during implantation can also improve residual curvature and postoperative penile length.[44],[45],[46],[47] Surgical techniques include manual penile modeling, concurrent plication for refractory curvature, endoscopic plaque resection, and plaque incision/grafting.[47] In patients with severe penile shortening, the double dorsoventral sliding technique can also be used to recover penile length during PP placement.[48] Within this context, both surgeon and patient should be aware of added complexity and ensure that expectations are managed accordingly.

Identification of the CURSED patient

While the above-mentioned risk factors may be attenuated or treated prior to PP implantation, psychosocial risk factors and unrealistic patient expectations are difficult to overcome. As such, the identification of the “difficult patient” is critical to maintaining postoperative satisfaction and operative success. To aide, Trost et al.[49] conducted a review of cosmetic literature and illustrated seven key characteristics associated with high rates of postoperative dissatisfaction: the CURSED patient who is compulsive/obsessive, unrealistic, seeking revision, surgeon shopping, entitled, in denial, and/or psychiatric. While these characteristics may not be immediately recognizable during initial consultations, focused discussion and input from medical office staff can facilitate their surfacing. Specific examples are provided in [Table 3]. However, this list is by no means exhaustive and surgeons should trust their intuition during preoperative visits – by definition, a patient with unreasonable expectations cannot be fully satisfied, even in the setting of a great surgical outcome.
Table 3: Risk factors associated with postinflatable penile prosthesis surgery dissatisfaction – compulsive, unrealistic, revision, surgeon shopping, entitled, denial, psychiatric patient

Click here to view



  Preoperative Optimization and Counseling Top


After patient selection for PP implantation, informed consent and preoperative counseling provides a formal platform to plan, anticipate, and discuss risk of complications. The risk of infection with virgin inflatable penile prosthesis (IPP) implantation ranges from <1% to 4%, increasing up to 10% in patients seeking a revision.[50],[51],[52] Although these risks are appreciably low in contemporary series, they are associated with significant morbidity, potential need for revision or explantation, psychological trauma, and financial burden.[53] As such, both patients and surgeons should be aware of the risk profiles that create a predisposition for infection and how to minimize the associated risks.

Surgeon-amenable factors

The influence of surgeon experience on preoperative optimization and patient risk profiling is important to recognize. As nearly all skills are dependent on frequency of repetition, low-volume surgeons with limited specialty training are more likely to have higher complication rates and reduced operative success, as compared to higher-volume and more experienced surgeons.[54],[55],[56],[57] In the context of PP implantation, a 2009 retrospective review by Henry et al.[54] found significantly shorter cylinder lengths of prostheses placed, higher complication rates, longer operative times, and shorter revision-free survival of PP implantation among low-volume surgeons. Similarly, these findings were echoed in an analysis of a national penile prosthesis database.[58] Recognition of correlations such as these not only allows for realistic patient counseling, but also indicates that surgeons should be able to recognize when a patient's risk profile is ill-matched to the operation, avoid surgery in complex patients, and refer to specialized practices when appropriate. Additional training may also be warranted to improve surgical skills or to expand surgical offerings.

Similarly, the recent increase in outpatient PP implantation speaks further to surgeon-amendable factors and preoperative optimization.[58] While some argue that this shift toward shorter hospital stays is due to insurance reimbursement rates, others view it illustrative of increased surgeon preparedness and willingness to invest time preoperatively.[58],[59],[60] A 2019 study of 16 923 patients by Kirshenbaum et al.,[61] for instance, found that men with inpatient admissions within 90 days of PP implantation were 3 times more likely to be readmitted within 30 days, 1.7 times more likely to have a length of stay for 2 days or greater, and 1.7 times more likely to have device complications after PP implantation. These models are useful reminders of easily modifiable approaches to preoperative assessment and risk profiling: investment in medical optimization and, in some cases, delayed surgery can alleviate risk and improve surgical outcomes.

Patient-amenable factors

Shared decision-making between patient and surgeon is also key to preoperative optimization and risk profiling. In this regard, controversies in the current guidelines should be discussed, among which includes perioperative use of antibiotic prophylaxis. The current AUA Best Practice Policy Statement in Antimicrobial Prophylaxis recommends <24 h of antibiotic therapy after PP insertion, citing data from orthopedic literature.[62] In contrast, a panel of North American expert prosthetic surgeons recommends the use of postoperative antibiotics (of varying types), from 5 to 14 days after surgery.[63] Even further, a popular approach is one with a “better safe than sorry” mentality, with many experts advocating for broader approaches to antibiotic prophylaxis despite lack of Level 1 evidence. Regardless of paucity in the current literature, patients should be counseled on the risks associated with postoperative antibiotic prophylaxis, in addition to the current disagreement between practice guidelines, expert opinion, and surgeon experience.

Along these lines, patients with spinal cord injuries are universally recognized to be at an increased risk for postoperative infection and are consequently more often prescribed perioperative antibiotic prophylaxis.[64] However, a study by Selph and colleagues at the University of North Carolina deconstructed the pathophysiology of infection in these patients into highly generalizable and patient-amenable risk factors.[64],[65],[66] Risk profiles generally included those who (1) were stationary, (2) had reduced distal blood circulation, (3) had suboptimal hygiene, (4) were immunocompromised, and (5) who experienced prolonged catheterization. Similarly, a retrospective review by Balen et al.[66] further identified risk factors contributing to infection in polysubstance abusers. Rather than the substance abuse itself, the authors found that the likelihood of abuse correlated closely with low socioeconomic status, poverty, and other comorbidity – factors more likely culprit of infection.[66] In these settings, addressing the parts may be more effective than the whole. Patients presenting with these risk profiles should be referred to preventative measures such as discontinued steroid use, preoperative management of comorbid conditions, avoidance of indwelling catheterization, preoperative skin cleansing, and compliance with antibiotic regimens.

Perhaps more applicable to the general patient undergoing PP implantation is maintenance of a healthy lifestyle. Although patients who have never smoked and have a healthy diet are considered optimal candidates, perioperative modification of risky behaviors has also shown to be an effective strategy to increasing operative success.[67],[68] A meta-analysis by Sorenson,[67] for example, demonstrated that smokers who quit smoking 4 weeks prior to surgery were able to reduce their risk of infection by over 50%. Further, balanced meals and that promote tissue healing (i.e., lean meats, green and yellow vegetables, citrus fruits, dairy products, and whole wheat breads and grains) are widely recommended during the recovery process.[68]


  Impact of Patient Risk Profiles on Device Selection Top


Currently available penile prostheses have achieved high ratings in regard to safety and reliability.[69] While adverse events are increasingly uncommon, possibility of infection, erosion, or mechanical malfunction postimplantation still remains.[47],[50],[53] In this regard, patient risk profiling and device selection remains key to preventing adverse events, ensuring patient satisfaction, and maintaining device longevity.

Patient and surgeon preference

There are two primary manufacturers of semirigid and inflatable penile prostheses in the United States: AMS (American Medical Systems, Minnetonka, MN, USA) and Coloplast Ltd. (Peterborough, Cambs, England), each with their own uniquities that complement patient profiles. In general, semirigid rods are favored for their excellent mechanical reliability and ease of implant via subcoronal, penoscrotal, or infrapubic incisions.[47] However, these devices also have the disadvantage of an always erect penis that is not easily concealed. There are also two- and three-component inflatable devices, each also with their own advantages and disadvantages. Three-component prosthesis feel softer than two-piece devices when deflated, have better cosmetic results, and ensure more natural erections. However, these devices also have increased potential for malfunction and often require more complicated surgical approaches.[70] As a general guide, patient and partner generally prefer inflatable prostheses for their ability to mimic both the flaccid and erect states of a normally functioning penis.[5],[6],[46],[47] While rigidity is achieved by semirigid and inflatable prosthesis alike, these differences in cosmetic result and “naturalness” of the devices drive patient preference. These priorities should be weighed against potential case complexity, surgical technique, and potential need for revisions.

Advances in prosthetic implants

Both AMS and Coloplast Ltd. have recognized the need for patient-device tailoring and infection management. AMS produces the 700™ series: the AMS 700 CX, AMS 700 LGX, and the AMS CXR. Within the context of risk profiling, the AMS CXR is the optimal choice for cases of fibrosis of corpora cavernosa, scarred corporal bodies, and stenotic proximal corpora.[69],[70],[71] All three models include a polymer coating, Parylene™, designed to increase device longevity; and Inhibizone™, an external layer made of minocycline and rifampin to prevent bacterial colonization. Comparable to these innovations, Coloplast Ltd. produces the alpha 1; the Titan, which adds an additional hydrophilic coating to absorb antibiotics when immersed; and the Titan narrow-base, designed specifically for scarred or fibrotic corpora. All devices of both companies employ kink-free silicone tubing and improved tubing connections to prevent mechanical failure.

Clinical considerations

Several clinical factors also determine the optimal penile prosthesis for a patient and, in this regard, patient risk profiles should be considered to maximize benefit. Older men who have limited mental or manual dexterity, for example, are often better served with semirigid implants, given the challenges associated with the pump and deflation mechanisms of inflatable devices. In contrast, patients with spinal cord injury or diminished sensation in the penis may benefit most with an inflatable device, given the potential for prolonged, excessive pressure against the prosthetic rods, which increases the likelihood of erosion.[69],[71] Even yet, patients with Peyronie's disease should only consider prostheses for girth expansion, as length expansion may exacerbate curvature.[47] A summary of advantages and disadvantages of each prosthesis is presented in [Table 4].
Table 4: Risk profiles driving device selection – advantages and disadvantages of semirigid versus inflatable prostheses

Click here to view


Although patient-specific profiles are important to evaluate when considering intra-manufacturer devices, there is also some evidence to inform inter-manufacturer selection. In 2016, Scovell and colleagues addressed this question via biomechanical testing on the four most commonly utilized prostheses (i.e., AMS 700 LGX 18 cm/22 cm versus the Coloplast Titan 18 cm/21 cm) and highlighted key differences between the manufacturers' designs. When compared to the Coloplast Titan, the AMS 700 LGX expanded mostly longitudinally, less circumferentially, and was highly dependent on pressure.[72] To translate these findings to clinical practice, the AMS 700 LGX may be optimal for men who are concerned with penile length while potentially troublesome for patients who have corporal fibrosis. Similarly, the Coloplast Titan is considered to be a preferred product for men who need higher axial loading during penetration and in men concerned with a lower-hanging phallus postimplantation. Overall, this study is yet another example of the importance of patient-oriented device selection.


  Intraoperative Considerations Top


Finally, there are a number of intraoperative considerations that are used in an effort to reduce patient risk during PP implantation. While many of these are perhaps widespread practices, we seek to explore their advantages within specific patient populations and call for evidence-based policies to match.

Preoperative use of chlorhexidine wash

The preoperative use of chlorhexidine washes is one of the easiest and most commonly carried out preventative measures prior to PP implantation. The literature suggests reduction of surgical site infection with the use of chlorhexidine washes when compared to use of a povidone-iodine wash.[73],[74] A 2013 prospective, randomized study of patients undergoing urological prosthetic operations found that chlorhexidine was superior to povidone-iodine in eradicating skin flora at the surgical site before prosthesis implantation.[74] The use of preoperative chlorhexidine washes are recommended for their ease to be carried out and their superiority to povidone-iodine washes. Patients at higher risk for infection due to virulent skin flora or positive urine culture, for example, can be more persistent in the utilization of chlorhexidine wash.

Surgical site hair removal

Informed by general surgery literature, most institutions have specific policies mandating the use of electric clippers for all surgical site hair removal. However, due to the delicate, irregular, and elastic skin of the male genitalia, urologists often prefer razors.[73] Several randomized control trials have compared the use of electric clippers versus razors, without any evidence to support a decrease in infection for either device.[75] Because these trials suggest no advantage of one over the other, the Sexual Medicine Society of North American recommends surgeons be permitted to use their choice for preoperative preparation and patients be instructed not to shave or clip themselves prior to surgery.[76]

Intraoperative antibiotics

As with all open surgical procedures, antibiotics at the time of incision are mandatory. The American Urological Association recommends perioperative use of an aminoglycoside (or aztreonam) and a first- or second-generation cephalosporin and vancomycin. Both may be continued up to 24 h after surgery.[62] Alternative antibiotics include ampicillin/sulbactam, ticarcillin/clavulanate, and piperacillin/tazobactam for <24 h, given no previous bacterial colonization. While survey data show large variation in preference of antibiotic use, their use is often tailored by contraindication, side effect profiles, and patient preference.[77]

Surgical drain placement

To date, the efficacy and safety of closed-suction drainage of the scrotum remains a topic of debate. Those that critique placement of a surgical drain suggest an increase in risk of infection via retrograde migration of bacteria as commonly seen in wound drains of nonurologic procedures.[64],[65], 69, [70] Further, closed-suction drainage systems are more invasive, require postoperative removal, and can prevent same-day discharge. These factors are weighed against decreased risk of edema, ecchymosis, and hematoma formation of the scrotum. In 2005, Sadeghi-Nejad and colleagues retrospectively reviewed 425 patients undergoing primary three-piece PP implantation with closed-suction drain placement for 12–24 h after surgery. With infection rates comparable to other series, surgical drain placement did not significantly increase infection rates in this series. Further, this cohort benefited from low incidence of postoperative hematoma formation, swelling, and ecchymosis.[78] Without prospective randomized control trials on drain placement following PP implantation, benefit of closed-suction drains remains unclear. Until Level 1 evidence is found to support its use, drain placement remains a surgeon-driven preference.

Sterile procedures and the “no-touch” technique

In 2011, Eid presented the “no-touch” technique for PP implantation.[79] The traditional approach is employed through the penoscrotal raphe, until Buck's fascia is reached. Then, new and unused instruments (and gloves) are utilized to cover the surgical field with a clear drape. Above the original incision site, a small opening in the drape is created where the remainder of the procedure is performed. This approach allows for minimal to no contact with the patient's skin, surgeon's hands, surgical instruments, and the implant. Although this “no-touch” technique increases operating time by 10–20 min and creates additional cost via new instruments, several prospective series have shown this technique to be effective in reducing risk of contamination and subsequent infection.[80] Given the newness of this technique, however, future studies to establish its cost-effectiveness and (potentially) refine its use are anticipated.


  Conclusions Top


While penile prosthetic surgery enjoys high rates of patient satisfaction, the potential for complication and infection remains. Factors increasing complexity of penile prosthesis implantation range from medical comorbidity, patient- and surgeon-oriented characteristics to proper device selection and differences in intraoperative technique. In these regards, candid risk profiling is key to ensuring the best possible result.


  Author Contributions Top


LMH and MMO synthesized data, drafted, and finalized manuscript; FAY made critical revisions and finalized manuscript. All authors read and approved the final version of the manuscript and agreed with the order presentation of the authors.


  Competing Interests Top


FAY: Consultant, Coloplast, Boston Scientific. LMH and MMO declared no competing interests.



 
  References Top

1.
Scott FB, Bradley WE, Timm GW. Management of erectile impotence. Use of implantable inflatable prosthesis. Urology 1973; 2: 80–2.  Back to cited text no. 1
    
2.
Small MP, Carrion HM. Penile prosthesis: new implant for management of impotence. J Fla Med Assoc 1975; 62: 21–5.  Back to cited text no. 2
    
3.
Wilson SK, Delk JR, Salem EA, Cleves MA. Long-term survival of inflatable penile prostheses: single surgical group experience with 2,384 first-time implants spanning two decades. J Sex Med 2007; 4: 1074–9.  Back to cited text no. 3
    
4.
Pryor MB, Carrion R, Wang R, Henry G. Patient satisfaction and penile morphology changes with postoperative penile rehabilitation 2 years after Coloplast Titan prosthesis. Asian J Androl 2016; 18: 754–8.  Back to cited text no. 4
    
5.
Gentile G, Franceschelli A, Massenio P, Tuccio A, Cocci A, et al. Patient's satisfaction after 2-piece inflatable penile prosthesis implantation: an Italian multicentric study. Arch Ital Urol Androl 2016; 88: 1–3.  Back to cited text no. 5
    
6.
Akakpo W, Pineda MA, Burnett AL. Critical analysis of satisfaction assessment after penile prosthesis surgery. Sex Med Rev 2017; 5: 244–51.  Back to cited text no. 6
    
7.
Pineda M, Burnett AL. Penile prosthesis infections-a review of risk factors, prevention, and treatment. Sex Med Rev 2016; 4: 389–98.  Back to cited text no. 7
    
8.
Hartman RP, Kawashima A, Takahashi N, LeRoy AJ, King BF. Inflatable penile prosthesis (IPP): diagnosis of complications. Abdom Radiol (NY) 2016; 41: 1187–96.  Back to cited text no. 8
    
9.
Narang GL, Figler BD, Coward RM. Preoperative counseling and expectation management for inflatable penile prosthesis implantation. Transl Androl Urol 2017; 6: S869–80.  Back to cited text no. 9
    
10.
Kovac JR. Informed consent for penile prosthesis surgery. Transl Androl Urol 2017; 6: 881–2.  Back to cited text no. 10
    
11.
American Urological Association Education and Research, Inc. Erectile dysfunction: AUA guideline. J Urol 2018; 200: 633–41.  Back to cited text no. 11
    
12.
International Society for Sexual Medicine. Penile prosthesis surgery: current recommendations from the international consultation on sexual medicine. J Sex Med 2016; 13: 489–518.  Back to cited text no. 12
    
13.
Lane-Cordova AD, Kershaw K, Liu K, Herrington D, Lloyd-Jones DM. Association between cardiovascular health and endothelial function with future erectile dysfunction: the multi-ethnic study of atherosclerosis. Am J Hypertens 2017; 30: 815–21.  Back to cited text no. 13
    
14.
Bratu O, Oprea I, Marcu D, Spinu D, Niculae A. Erectile dysfunction post-radical prostatectomy – a challenge for both patient and physician. J Med Life 2017; 10: 13–8.  Back to cited text no. 14
    
15.
Campbell J, Alzubaidi R. Understanding the cellular basis and pathophysiology of Peyronie's disease to optimize treatment for erectile dysfunction. Transl Androl Urol 2017; 6: 46–59.  Back to cited text no. 15
    
16.
Chen J, Chen Y, Chen G, Dai Y, Yao Z. Altered brain networks in psychogenic erectile dysfunction: a resting-state fMRI study. Andrology 2017; 5: 1073–81.  Back to cited text no. 16
    
17.
Mulhall JP, Luo X, Zou KH, Stecher V, Galaznik A. Relationship between age and erectile dysfunction diagnosis or treatment using real-world observational data in the USA. Int J Clin Pract 2016; 70: 1012–8.  Back to cited text no. 17
    
18.
Rastrelli G, Corona G, Mannucci E, Maggi M. Vascular and chronological age in men with erectile dysfunction: a longitudinal study. J Sex Med 2016; 13: 200–8.  Back to cited text no. 18
    
19.
Katsiki N, Wierzbicki AS, Mikhailidis DP. Erectile dysfunction and coronary heart disease. Curr Opin Cardiol 2015; 30: 416–21.  Back to cited text no. 19
    
20.
Rocha E. Cardiovascular risk scores: usefulness and limitations. Rev Port Cardiol 2016; 35: 15–8.  Back to cited text no. 20
    
21.
Woodward M. On validation of cardiovascular risk scores. BMJ 2016; 354: i4483.  Back to cited text no. 21
    
22.
Chen YL, Cheng CL, Huang JL, Yang NI, Chang HC. Mortality prediction using CHADS2/CHA2 DS2-VASc/R2 CHADS2 scores in systolic heart failure patients with or without atrial fibrillation. Medicine (Baltimore) 2017; 96: e8338.  Back to cited text no. 22
    
23.
Patell R, Gutierrez A, Rybicki L, Khorana AA. Usefulness of CHADS2 and CHA2 DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation. Am J Cardiol 2017; 120: 2182–6.  Back to cited text no. 23
    
24.
Gupta AD, Streiff M, Resar J, Schoenberg M. Coronary stent management in elective genitourinary surgery. BJU Int 2012; 110: 480–4.  Back to cited text no. 24
    
25.
Stough WG, Patterson JH. Role and value of clinical pharmacy in heart failure management. Clin Pharmacol Ther 2017; 102: 209–12.  Back to cited text no. 25
    
26.
Houston BA, Kalathiya RJ, Kim DA, Zakaria S. Volume overload in heart failure: an evidence-based review of strategies for treatment and prevention. Mayo Clin Proc 2015; 90: 1247–61.  Back to cited text no. 26
    
27.
Culkin DJ, Exaire EJ, Green D, Soloway MS, Gross AJ, et al. Anticoagulation and antiplatelet therapy in urological practice: ICUD/AUA review paper. J Urol 2014; 192: 1026–34.  Back to cited text no. 27
    
28.
Rahman A, Latona J. New oral anticoagulants and perioperative management of anticoagulant/antiplatelet agents. Aust Fam Physician 2014; 43: 861–6.  Back to cited text no. 28
    
29.
Dryden M, Baguneid M, Eckmann C, Corman S, Stephens J, et al. Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections. Clin Microbiol Infect 2015; 21: S27–32.  Back to cited text no. 29
    
30.
Leung M, Leung DY. Coronary microvascular function in patients with type 2 diabetes mellitus. EuroIntervention 2016; 11: 1111–7.  Back to cited text no. 30
    
31.
Karki DB, Yadava SK, Pant S, Thusa N, Dangol E, et al. Prevalence of sensory neuropathy in type 2 diabetes mellitus and its correlation with duration of disease. Kathmandu Univ Med J (KUMJ) 2016; 14: 120–4.  Back to cited text no. 31
    
32.
Bishop JR, Moul JW, Sihelnik SA, Peppas DS, Gormley TS, et al. Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol 1992; 147: 386–8.  Back to cited text no. 32
    
33.
Habous M, Tal R, Tealab A, Soliman T, Nassar M, et al. Defining a glycated haemoglobin (HbA1c) level that predicts increased risk of penile implant infection. BJU Int 2018; 121: 293–300.  Back to cited text no. 33
    
34.
Wilson SK, Carson CC, Cleves MA, Delk JR. Quantifying risk of penile prosthesis infection with elevated glycosylated hemoglobin. J Urol 1998; 159: 1537–9.  Back to cited text no. 34
    
35.
Canguven O, Talib R, El Ansari W, Khalafalla K, Al Ansari A. Is Hba1c level of diabetic patients associated with penile prosthesis implantation infections? Aging Male 2018; 9: 1–6.  Back to cited text no. 35
    
36.
Christodoulidou M, Pearce I. Infection of penile prostheses in patients with diabetes mellitus. Surg Infect (Larchmt) 2016; 17: 2–8.  Back to cited text no. 36
    
37.
Wilson SK, Mora-Estaves C, Egydio P, Ralph D, Habous M. Glans necrosis following penile prosthesis implantation: prevention and treatment suggestions. Urology 2017; 107: 144–8.  Back to cited text no. 37
    
38.
Segal RL, Camper SB, Ma L, Burnett AL. Prediction model for penile prosthesis implantation for erectile dysfunction management. Curr Med Res Opin 2014; 30: 2131–7.  Back to cited text no. 38
    
39.
Bennet N, Huang IS. Inflatable penile prosthesis in the radical prostatectomy patient: a review. F1000Res 2018; 7: 1–8.  Back to cited text no. 39
    
40.
Dadhich P, Hockenberry M, Kirby EW, Lipshultz L. Penile prosthesis in the management of erectile dysfunction following cancer therapy. Transl Androl Urol 2017; 6: S883–9.  Back to cited text no. 40
    
41.
Hartman RJ Jr., Helfand BT, McVary KT. Outcomes of lateral retroperitoneal reservoir placement of three-piece penile prosthesis in patients following radical prostatectomy. Int J Impot Res 2010; 22: 279–83.  Back to cited text no. 41
    
42.
Perito PE. Ectopic reservoir placement – no longer in the space of the Retzius. J Sex Med 2011; 8: 2395–8.  Back to cited text no. 42
    
43.
Loh-Doyle J, Patil MB, Sawkar H, Wayne K, Boyd SD. 3-piece inflatable penile prosthesis placement following radical cystoprostatectomy and urinary diversion: technique and outcomes. J Sex Med 2018; 17: 907–13.  Back to cited text no. 43
    
44.
Shindel W, Bullock TL, Brandes S. Urologist practice patterns in the management of Peyronie's disease: a nationwide survey. J Sex Med 2008; 5: 954–64.  Back to cited text no. 44
    
45.
American Urological Association Education and Research, Inc. Peyronie's Disease: AUA Guideline. J Urol 2015; 194: 745–53.  Back to cited text no. 45
    
46.
Montorsi F, Guazzoni F, Bergamaschi F, Rigatti P. Patient-partner satisfaction with semirigid penile prostheses for Peyronie's disease: a 5-year followup study. J Urol 1993; 153: 1819–21.  Back to cited text no. 46
    
47.
Anaissie J, Yafi FA. A review of surgical strategies for penile prosthesis implantation in patients with Peyronie's disease. Transl Androl Urol 2016; 5: 342–50.  Back to cited text no. 47
    
48.
Rolle L, Ceruti C, Timpano M, Sedigh O, Destefanis P, et al. A new, innovative, lengthening surgical procedure for Peyronie's disease by penile prosthesis implantation with double dorsal-ventral patch graft: the “sliding technique”. J Sex Med 2012; 9: 2389–95.  Back to cited text no. 48
    
49.
Trost LW, Baum N, Hellstrom WJ. Managing the difficult penile prosthesis patient. J Sex Med 2013; 10: 893–906.  Back to cited text no. 49
    
50.
Trost L, Wanzek P, Bailey G. A practical overview of considerations for penile prosthesis placement. Nat Rev Urol 2016; 13: 33–46.  Back to cited text no. 50
    
51.
Mandava SH, Serefoglu EC, Freier MT, Wilson SK, Hellstrom WJ. Infection retardant coated inflatable penile prostheses decrease the incidence of infection: A systematic review and meta-analysis. J Urol 2012; 188: 1855–60.  Back to cited text no. 51
    
52.
Wilson SK, Zumbe J, Henry GD, Salem EA, Delk JR, et al. Infection reduction using antibiotic-coated inflatable penile prosthesis. Urology 2007; 70: 337–40.  Back to cited text no. 52
    
53.
Lujan S, Rogel R, Broseta E, Boronat F. Local treatment of penile prosthesis infection as alternative to immediate salvage surgery. Sex Med 2016; 4: e255–8.  Back to cited text no. 53
    
54.
Henry GD, Kansal NS, Callaway M, Grisby T, Henderson J, et al. Centers of excellence concept and penile prostheses: an outcome analysis. J Urol 2009; 181: 1264–8.  Back to cited text no. 54
    
55.
Onyeji IC, Sui W, Pagano MG, Weinberg AC, James MB, et al. Impact of surgeon case volume on reoperation rates after inflatable penile prosthesis surgery. J Urol 2017; 197: 223–9.  Back to cited text no. 55
    
56.
Ziegemann M, Kohler TS, Bailey GC, Miest T, Alom M, et al. Surgical patient selection and counseling. Transl Androl Urol 2017; 6: 609–19.  Back to cited text no. 56
    
57.
McAbee KE, Pearlman AM, Terlecki RP. Infection following penile prosthesis placement at an academic training center remains low despite involvement of surgeons-in-training. Investig Clin Urol 2018; 59: 342–7.  Back to cited text no. 57
    
58.
Alwaal A, Harris CR, Hussein AA, Sanford TH, McCulloch CE, et al. The decline of inpatient penile prosthesis over the 10-year period, 2000-2010. J Sex Med 2015; 3: 280–6.  Back to cited text no. 58
    
59.
Mulhall JP, Bloom K. Comparison of in-patient and out-patient penile prosthesis surgery. Int J Impot Res 2001; 13: 251–4.  Back to cited text no. 59
    
60.
Mondaini N, Sarti E, Giubilei G, Gavazzi A, Costanzi A, et al. Penile prosthesis surgery in out-patient setting: Effectiveness and costs in the “spending review” era. Arch Ital Urol Androl 2014; 86: 161–3.  Back to cited text no. 60
    
61.
Kirshenbaum EJ, Nelson M, Hehemann MC, Kothari AN, Eguia E, et al. Impact of post-hospital syndrome on penile prosthesis outcomes: a period of global health risk. J Urol 2019; 201: 154–9.  Back to cited text no. 61
    
62.
American Urological Association Education and Research, Inc. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008; 179: 1379–90.  Back to cited text no. 62
    
63.
Darouiche RO, Bella AJ, Boone TB, Brock G, Broderick GA, et al. North American consensus document on infection of penile prostheses. Urology 2013; 82: 937–42.  Back to cited text no. 63
    
64.
Elmussareh M, Goddard JC, Summerton DJ, Terry TR. Minimising the risk of device infection in penile prosthetic surgery: a UK perspective. J Clin Urol 2013; 6: 280–8.  Back to cited text no. 64
    
65.
Selph JP, Carsson CC 3rd. Penile prosthesis infection: approaches to prevention and treatment. Urol Clin North Am 2011; 38: 227–35.  Back to cited text no. 65
    
66.
Balen A, Gross MS, Phillips EA, Henry GD, Munarriz R. Active polysubstance abuse concurrent with surgery as a possible newly identified infection risk factor in inflatable penile prosthesis placement based on a retrospective analysis of health and socioeconomic factors. J Sex Med 2016; 13: 697–701.  Back to cited text no. 66
    
67.
Sorenson LT. Wound healing and infection in surgery. The clinical impact of smoking and smoking cessation: a systematic review and meta-analysis. Arch Surg 2012; 147: 373–83.  Back to cited text no. 67
    
68.
Russell L. The importance of patients' nutritional status in wound healing. Br J Nurs 2001; 10: S44–9.  Back to cited text no. 68
    
69.
Hossein SN. Penile prosthesis surgery: a review of prosthetic devices and associated complications. J Sex Med 2007; 4: 296–309.  Back to cited text no. 69
    
70.
Bettocchi C, Palumbo F, Spilotros M, Palazzo S, Saracino GA. Penile prostheses. Ther Adv Urol 2010; 2: 35–40.  Back to cited text no. 70
    
71.
Lazarou S, Reyes-Valejo L, Morgentaler A. Technical advances in penile prostheses. J Long Term Eff Med Implants 2006; 16: 235–47.  Back to cited text no. 71
    
72.
Scovell JM, Liehui G, Barrera EV, Wilson SK, Carrion RE, et al. Longitudinal and horizontal load testing of inflatable penile implant cylinders of two manufacturers: an ex vivo demonstration of inflated rigidity. J Sex Med 2016; 13: 1750–7.  Back to cited text no. 72
    
73.
Darouiche RO, Wall MJ Jr, Itani KM, Otterson MF, Webb AL, et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010; 362: 18–26.  Back to cited text no. 73
    
74.
Yeung LL, Grewal S, Bullock A, Lai HH, Brandes SB, et al. A comparison of chlorhexidine-alcohol versus povidone-iodine for eliminating skin flora before genitourinary prosthetic surgery: a randomized controlled trial. J Urol 2013; 189:136–40.  Back to cited text no. 74
    
75.
Grober ED, Domes T, Fanipour M, Copp JE. Preoperative hair removal on the male genitalia: clippers vs. razors. J Sex Med 2013; 10: 589–94.  Back to cited text no. 75
    
76.
Sexual Medicine Society of North America; Position Statements: Razors and Preoperative Preparation of the Male Genitalia. Available from: http://www.smsna.org/ V1/about/position-statements. [Last accessed on 2019 Jun 11].  Back to cited text no. 76
    
77.
Wosnitzer MW, Greenfield JM. Antibiotic patterns with inflatable penile prosthesis insertion. J Sex Med 2011; 8: 1521–8.  Back to cited text no. 77
    
78.
Sadeghi-Nejad H, Ilbeigi P, Wilson SK, Delk JR, Siegel A, et al. Multi-institutional outcome study on the efficacy of closed-suction drainage of the scrotum in three-piece inflatable penile prosthesis surgery. Int J Impot Res 2005; 17: 535–8.  Back to cited text no. 78
    
79.
Eid JF. No-touch technique. J Sex Med 2011; 8: 5–8.  Back to cited text no. 79
    
80.
Eid JF. Penile implant: review of “no-touch” technique. Sex Med Rev 2016; 4: 294–300.  Back to cited text no. 80
    



 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4]



 

 
Top
 
 
  Search
 
 Search Pubmed for
 
    -  Huynh LM
    -  Osman MM
    -  Yafi FA
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)  

 
  In this article
Abstract
Introduction
Patient Selectio...
Preoperative Opt...
Impact of Patien...
Intraoperative C...
Conclusions
Author Contributions
Competing Interests
References
Article Tables

 Article Access Statistics
    Viewed230    
    PDF Downloaded15    

Recommend this journal